Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Net Cash Flow (2016 - 2025)

Lisata Therapeutics' Net Cash Flow history spans 13 years, with the latest figure at -$3.0 million for Q4 2025.

  • For Q4 2025, Net Cash Flow rose 5.9% year-over-year to -$3.0 million; the TTM value through Dec 2025 reached -$264000.0, up 95.83%, while the annual FY2025 figure was -$264000.0, 95.83% up from the prior year.
  • Net Cash Flow reached -$3.0 million in Q4 2025 per LSTA's latest filing, down from $2.2 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $8.7 million in Q3 2023 to a low of -$9.8 million in Q4 2023.
  • Average Net Cash Flow over 3 years is -$1.3 million, with a median of -$3.1 million recorded in 2024.
  • Peak YoY movement for Net Cash Flow: crashed 201.85% in 2024, then surged 646.52% in 2025.
  • A 3-year view of Net Cash Flow shows it stood at -$9.8 million in 2023, then skyrocketed by 66.85% to -$3.2 million in 2024, then grew by 5.9% to -$3.0 million in 2025.
  • Per Business Quant, the three most recent readings for LSTA's Net Cash Flow are -$3.0 million (Q4 2025), $2.2 million (Q3 2025), and -$3.4 million (Q2 2025).